Insulin autoantibody (IAA) (IAA)

Insulin autoantibodies (IAA) and proinsulin autoantibodies (PAA) are self-reactive immunoglobulins that target endogenous insulin and its precursor, proinsulin, respectively. They serve as critical biomarkers in the early detection and risk assessment of Type 1 Diabetes Mellitus (T1DM), often appearing as the first serological evidence of beta-cell autoimmunity in young children (PMID: 28899119). While these antibodies are not direct therapeutic targets, their presence indicates an underlying T-cell mediated destruction of the pancreas. In rare instances, such as Insulin Autoimmune Syndrome (Hirata disease), high concentrations of IAA can lead to severe metabolic disturbances, including paradoxical postprandial hypoglycemia (PMID: 31536301). Management of conditions associated with these antibodies typically involves immunomodulatory therapies like Teplizumab, which is designed to delay the progression of T1DM by modulating T-cell activity (PMID: 31157982). Additionally, B-cell depletion therapies such as Rituximab have been investigated to reduce the production of these autoantibodies and preserve residual insulin secretion (PMID: 19846847). Monitoring IAA levels is essential for clinical trial stratification and for diagnosing rare forms of autoimmune hypoglycemia.

Other names

Proinsulin autoantibodyPAAAnti-insulin antibodyInsulin-binding antibodyInsulin autoantibodies

Therapeutic strategies involve immunomodulation to suppress the production of these autoantibodies or mitigate the T-cell mediated destruction of beta cells associated with their presence.